LMB-100

10/01/2016 - "Even large, well established tumors (600 mm(3)) underwent remission during three treatment cycles with RG7787. "
11/29/2022 - "Transcriptional profiling shows that LMB-100 treatment reshapes the tumor immune microenvironment by upregulating chemotaxis signals. "
11/29/2022 - "Our results show that the mice with tumor reached CRs and developed anti-tumor immunity after LMB-100 treatment alone. "
11/29/2022 - "Mice were treated with LMB-100, and mice with complete responses (CRs) were rechallenged with tumor cells to determine whether anti-tumor immunity developed. "
01/01/2020 - "LMB-100 caused a systemic inflammatory response and recruitment of CD8+ T cells in patients' tumors. "

11/15/2020 - "The MTD of LMB-100 was 140 µg/kg. Of the 10 patients with mesothelioma who were treated at doses of 170 µg/kg or 140 µg/kg, 8 had stable disease and 2 developed progressive disease. "
12/01/2018 - "LMB-100 is in clinical trials for the treatment of mesothelioma and pancreatic cancer. "
01/01/2020 - "LMB-100 plus pembrolizumab is now being evaluated in a prospective clinical trial for patients with mesothelioma."
11/15/2020 - "Ongoing phase 2 clinical trials are evaluating the combination of LMB-100 plus pembrolizumab in patients with treatment-refractory mesothelioma and non-small cell lung cancer."
11/15/2020 - "Phase 2 studies of LMB-100 plus pembrolizumab currently are ongoing for patients with mesothelioma and lung cancer. "

11/01/2014 - "RG7787 was also effective against gastric cancer cell lines MKN28, MKN45, and MKN74 in vitro, with subnanomolar IC50s. "
11/01/2014 - "RG7787 merits clinical testing for triple-negative breast and gastric cancers."
11/01/2014 - "Here, panels of triple-negative breast and gastric cancer cell lines were tested for surface MSLN expression, and for sensitivity to RG7787 in vitro and in animal models. "
11/01/2014 - "Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers."
01/01/2016 - "We report here that actinomycin D and RG7787 act synergistically to kill many mesothelin-positive cancer cell lines and produce major regressions of pancreatic and stomach cancer xenografts. "

12/22/2017 - "Finally, we evaluated the in-vivo efficacy of RG7787 in OvCa6668, a patient-derived ovarian cancer model with high levels of CA-125 expression. "
12/22/2017 - "In summary our data support clinical testing of RG7787 in ovarian cancer."
12/22/2017 - "Moreover when tested in-vitro on a panel of 12 ovarian cancer cell lines, RG7787 had high cytotoxic activity on COV644, Caov-4, and SNU-119 cells and fully inhibited growth of EFO-21, KURAMOCHI, OVSAHO, and Caov-3 cells with potency values ranging from 1 to 86 pM. "
12/22/2017 - "High prevalence of mesothelin-positive cases and a large unmet medical need make ovarian cancer a promising indication for the clinical development of RG7787. "

12/01/2018 - "LMB-100 is in clinical trials for the treatment of mesothelioma and pancreatic cancer. "
10/31/2018 - "We found that treatment of pancreatic cancer cells with LMB-100 for 24⁻48 h did not change total protein level despite inducing protein synthesis inhibition (PSI). "
07/01/2015 - "Correction: In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer."
08/01/2014 - "In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer."
06/26/2015 - "RG7787 (anti-mesothelin recombinant immunotoxin) is highly cytotoxic to pancreatic cancer cell lines, but with limited activity in vivo. "